Internal Reference Number: FOI_7875
Date Request Received: 09/04/2024 00:00:00
Date Request Replied To: 30/04/2024 00:00:00
This response was sent via: By Email
Request Summary: The treatment of Haemophilia A
Request Category: Researcher
| Question Number 1: How many haemophilia A patients are registered with your centre, and how many of these patients are classified as exhibiting mild, moderate, or severe disease. | |
| Answer To Question 1: Mild: 21 patients Moderate <5 patients Severe <5 patients | |
| Question Number 2: In the last three months, how many Haemophilia A patients, including on-demand patients, have been treated with the following products? • Advate • Adynovi • Elocta • Esperoct • Factor Eight Inhibitor Bypass Activity (FEIBA) • Hemlibra (standalone) • Hemlibra in combination with any Factor VIII • NovoEight • NovoSeven RT • Nuwiq • Obizur • Refacto AF • Any other products | |
| Answer To Question 2: • Advate <5 patients • Adynovi 0 patients • Elocta <5 patients. • Esperoct 0 patients • Factor Eight Inhibitor Bypass Activity (FEIBA) 0 patients • Hemlibra (standalone) 0 patients • Hemlibra in combination with any Factor VIII 0 patients • NovoEight 0 patients • NovoSeven RT 0 patients • Nuwiq 0 patients • Obizur 0 patients • Refacto AF 0 patients • Any other products 0 patients | |
| Question Number 3: For patients treated with Advate in the last three months, please provide: • the number of haemophilia A patients treated prophylactically • the number of haemophilia A patients treated for any other reason (e.g. surgery, on-demand, breakthrough bleeds) | |
| Answer To Question 3: • the number of haemophilia A patients treated prophylactically - 0 patients • the number of haemophilia A patients treated for any other reason (e.g. surgery, on-demand, breakthrough bleeds) <5 patients | |
| Question Number 4: In the last three months, how many patients were treated with the following products for severe Haemophila A ONLY? • Advate • Adynovi • Elocta • Esperoct • Factor Eight Inhibitor Bypass Activity (FEIBA) • Hemlibra (standalone) • Hemlibra in combination with any Factor VIII • NovoEight • NovoSeven RT • Nuwiq • Obizur • Refacto AF • Any other products | |
| Answer To Question 4: • Advate 0 Patients • Adynovi 0 Patients • Elocta >5 patients • Esperoct 0 Patients • Factor Eight Inhibitor Bypass Activity (FEIBA) 0 Patients • Hemlibra (standalone) 0 Patients • Hemlibra in combination with any Factor VIII 0 Patients • NovoEight 0 Patients • NovoSeven RT 0 Patients • Nuwiq 0 Patients • Obizur 0 Patients • Refacto AF 0 Patients • Any other products 0 Patients | |
| To return to the list of all the FOI requests please click here |
Our staff at SA¹ú¼Ê´«Ã½ Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
